Founded in October 2019, M28 Capital is a Connecticut-based hedge fund manager specializing in hedge funds that utilize a long/short equity strategy. The firm focuses primarily on companies within the life sciences and biotechnology sectors.
Marc Elia founded M28 Capital, a healthcare sector investment fund. Before establishing M28 Capital, from January 2012 to September 2019, Mr. Elia was a partner at Bridger Capital, an investment fund. He currently serves on the Board of Directors of Adagio Therapeutics, Adimab, and SQZ Biotechnologies. Mr. Elia earned a B.A. in Economics from Carleton College.
M28 Capital Management is a hedge fund managing discretionary assets totaling $157.7 million, as reported in their Form ADV dated March 2024. Serving six clients, their latest 13F filing for Q1 2024 disclosed holdings of $135.3 million in managed 13F securities, with a top 10 holdings concentration of 98.58%. The fund's largest holding is WAVE Life Sciences Ltd, with 7,000,000 shares held.
